Immunome, Inc. Payments to Acquire Debt Securities, Available-for-sale
Immunome, Inc. (IMNM) reported Payments to Acquire Debt Securities, Available-for-sale of $302.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-11
- Immunome, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Immunome, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $0.00.
- Immunome, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2024-12-31 was $73.87M.
- Immunome, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2024-09-30 was $0.00.
- Immunome, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $123.27M, a 33.93% decline from fiscal 2024.
- Immunome, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $186.56M, a 379.22% increase from fiscal 2023.
- Immunome, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $38.93M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $302.18M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $123.27M 10-K · filed 2026-03-03 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $123.27M 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $123.27M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $73.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $73.87M derived: sum of 2 quarters · filed 2026-03-03 | $186.56M 10-K · filed 2026-03-03 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $112.69M 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $112.69M 10-Q · filed 2025-08-06 | |||
| 2023-12-31 | $38.93M 10-K · filed 2025-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |